Literature DB >> 20408960

Utility of in situ demonstration of 1p loss and p53 overexpression in pathologic diagnosis of oligodendroglial tumors.

Takanori Hirose1, Keisuke Ishizawa, Shio Shimada.   

Abstract

To improve the diagnostic accuracy of oligodendroglial tumors and to find more convenient parameters that could predict the cytogenetic status, oligodendroglial and astrocytic tumors were cytogenetically and immunohistochemically investigated. Materials included 22 oligodendroglial tumors (15 oligodendrogliomas and 7 oligoastrocytomas) and 20 astrocytic tumors. 1p loss was examined with the fluorescence in situ hybridization (FISH) method. Expression of GFAP, Olig2 and p53 was immunohistochemically investigated and co-localization of GFAP and Olig2 was evaluated on double-immunostained sections. Furthermore, TP53 mutation analyses were carried out on three oligodendroglial tumors showing p53 protein overexpression with a direct sequence analysis. Our FISH studies demonstrated 1p loss in 73% of oligodendroglial tumors (80% oligodendrogliomas and 57% oligoastrocytomas) and in only 10% of astrocytic tumors. There were no clear-cut morphologic differences between 1p-deleted and 1p-intact oligodendroglial tumors. GFAP and Olig2 were expressed in most oligodendroglial and astrocytic tumors, and their cellular localization was almost independent of each other. Overexpression of p53 was observed in five oligodendroglial tumors, all of which were 1p-intact. In comparison, 16 oligodendroglial tumors with 1p deletion showed no overexpression of p53. TP53 missense mutations were detected in three of the p53 overexpressed oligodendroglial tumors studied. Our results suggest that 1p loss is almost specific to oligodendroglial tumors. Although the prediction of 1p status based solely on the morphologic features seems to be difficult, the immunohistochemistry for p53 is a useful tool in that p53 overexpression is closely related to the 1p-intact status in oligodendroglial tumors.
© 2010 Japanese Society of Neuropathology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20408960     DOI: 10.1111/j.1440-1789.2010.01116.x

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  4 in total

1.  TP53 and p53 statuses and their clinical impact in diffuse low grade gliomas.

Authors:  Emeline Gillet; Agusti Alentorn; Brahima Doukouré; Emeline Mundwiller; Hinke F van Thuijl; Hinke van Thuij; Jaap C Reijneveld; José Alfonso Meza Medina; Amélie Liou; Yannick Marie; Karima Mokhtari; Khê Hoang-Xuan; Marc Sanson; Jean-Yves Delattre; Ahmed Idbaih
Journal:  J Neurooncol       Date:  2014-03-04       Impact factor: 4.130

2.  Adult diffuse gliomas produce mRNA transcripts encoding EGFR isoforms lacking a tyrosine kinase domain.

Authors:  Angélique Guillaudeau; Karine Durand; Hélène Rabinovitch-Chable; Isabelle Pommepuy; Laura Mesturoux; Sandrine Robert; Alain Chaunavel; Jean-Jacques Moreau; François Labrousse
Journal:  Int J Oncol       Date:  2011-12-08       Impact factor: 5.650

3.  A "weighted" fluorescence in situ hybridization strengthens the favorable prognostic value of 1p/19q codeletion in pure and mixed oligodendroglial tumors.

Authors:  Rebecca Senetta; Ludovica Verdun di Cantogno; Luigi Chiusa; Isabella Castellano; Patrizia Gugliotta; Anna Sapino; Paola Cassoni
Journal:  J Neuropathol Exp Neurol       Date:  2013-05       Impact factor: 3.685

4.  ImmunoFISH is a reliable technique for the assessment of 1p and 19q status in oligodendrogliomas.

Authors:  Céline Duval; Marie de Tayrac; François Sanschagrin; Karine Michaud; Peter Vincent Gould; Stéphan Saikali
Journal:  PLoS One       Date:  2014-06-20       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.